[Clinical study of PSK as an adjuvant immunochemotherapeutic agent against gastric cancer]
Related Experiment Video
Updated: Sep 20, 2026
06:12
Evaluation of the Efficacy of the H. pylori Protein HP-NAP as a Therapeutic Tool for Treatment of Bladder Cancer in an Orthotopic Murine Model
Published on: May 29, 2015
Gan to Kagaku Ryoho. Cancer & Chemotherapy
|August 1, 1986
Abstract:
The effects of PSK in combination with Mitomycin C, Adriamycin and Tegafur were studied in 168 patients who underwent gastrectomy for gastric cancer. The study group receiving PSK showed improved survival and there was a significant difference in the estimated survival. An improved survival rate was also shown at stages III and IV, in the group given an FAM regimen and in the group with well differentiated adenocarcinoma.
